Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration

被引：2
作者：
Marta Ulldemolins
Carla Bastida
Mireia Llauradó-Serra
Chantal Csajka
Alejandro Rodríguez
Joan Ramon Badia
Ignacio Martín-Loeches
Dolors Soy
机构：
[1] Bellvitge University Hospital,Infectious Diseases – Internal Medicine Departments
[2] University of Barcelona,Pharmacy Department, Division of Medicines
[3] Hospital Clinic de Barcelona,Department of Nursing, School of Medicine and Health Sciences
[4] Universitat Internacional de Catalunya,Service of Clinical Pharmacology
[5] Centre Hospitalier Universitaire Vaudois,School of Pharmaceutical Sciences
[6] University of Geneva,Critical Care Department, Joan XXIII University Hospital, Institut d’Investigació Sanitària Pere Virgili (IISPV)
[7] University of Lausanne,Respiratory Intensive Care Unit
[8] Universitat Rovira I Virgili,Multidisciplinary Intensive Care Research Organization (MICRO), Critical Care Department
[9] Centro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES),undefined
[10] Hospital Clínic de Barcelona,undefined
[11] Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) – Fundació Clínic per la Recerca Biomèdica,undefined
[12] St James University Hospital,undefined
[13] Trinity Centre for Health Sciences,undefined
来源：
European Journal of Clinical Pharmacology | 2021年 / 77卷
关键词：
Ceftriaxone; Hypoalbuminemia; Pharmacokinetics; Critically ill patients; Septic shock; Continuous veno-venous hemodiafiltration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1169 / 1180
页数：11
相关论文
共 165 条
[1]  
Meyers B(1983)Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers Antimicrob Agents Chemother 24 812-814
[2]  
Srulevitch E(2001)The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients J Antimicrob Chemother 47 421-429
[3]  
Jacobson J(1998)Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1-10
[4]  
Hirschman S(2004)Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’ Nat Rev Microbiol 2 289-300
[5]  
Joynt GM(2020)b-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill J Antimicrob Chemother 75 429-433
[6]  
Lipman J(2001)Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock Crit Care Med 29 385-391
[7]  
Gomersall CD(2015)Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy? J Antimicrob Chemother 70 528-533
[8]  
Young RJ(2007)Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes Clin J Am Soc Nephrol 2 431-439
[9]  
Wong EL(2014)Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy Crit Care 18 227-110
[10]  
Gin T(2006)Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study BMJ 333 1044-810
12345678910